首页> 美国卫生研究院文献>American Journal of Cancer Research >Inhibitor of binding/differentiation 2 (Id2) is regulated by CCAAT/enhancer-binding protein-α (C/EBPα) and promotes the proliferation of hepatocellular carcinoma
【2h】

Inhibitor of binding/differentiation 2 (Id2) is regulated by CCAAT/enhancer-binding protein-α (C/EBPα) and promotes the proliferation of hepatocellular carcinoma

机译:结合/分化抑制剂2(Id2)受CCAAT /增强子结合蛋白α(C /EBPα)调节并促进肝细胞癌的增殖

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inhibitor of DNA binding/differentiation (Id2) is an important regulator involved in the initiation and progression of cancer. However, the function and mechanism of the regulation of Id2 in hepatocellular carcinoma (HCC) was unclear. In the present study, we found that the overexpression of Id2 increased HCC cell proliferation in vitro and in vivo. Knockdown of Id2 inhibited HCC cell proliferation in vitro and in vivo. Furthermore, knockdown of Id2 enhanced sorafenib-induced apoptosis in HCC. Conversely, overexpression of Id2 weakened sorafenib-induced apoptosis in HCC. In addition, the transcription factor CCAAT/enhancer-binding protein alpha (C/EBPα) bound to the Id2 promoter and decreased its expression in HCC cells. Therefore, all results suggest that Id2 promotes the proliferation of HCC cells by inhibiting cell apoptosis. Id2 may serve as a potential target in HCC therapy.
机译:DNA结合/分化抑制剂(Id2)是与癌症的发生和发展有关的重要调节剂。但是,尚不清楚肝细胞癌(HCC)中Id2调节的功能和机制。在本研究中,我们发现Id2的过表达增加了体外和体内HCC细胞的增殖。在体外和体内,抑制Id2抑制HCC细胞增殖。此外,Id2的敲除增强了索拉非尼诱导的HCC细胞凋亡。相反,Id2的过表达减弱了索拉非尼诱导的HCC细胞凋亡。此外,转录因子CCAAT /增强子结合蛋白α(C /EBPα)与Id2启动子结合并降低其在HCC细胞中的表达。因此,所有结果表明,Id2通过抑制细胞凋亡来促进HCC细胞的增殖。 Id2可能作为HCC治疗的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号